Arthrosurface(R) HemiCAP(R) Toe Resurfacing Implant Receives Reimbursement Approval from Major Insurance Carriers

Thursday, September 25, 2008 General News J E 4
FRANKLIN, Mass., Sept. 25 Arthrosurface, Inc.(, the developer of less-invasive jointresurfacing systems, announced that its HemiCAP(R) toe hemiarthroplastyproduct is now approved for reimbursement by Aetna and other major insurancecarriers.

"We are very pleased that Aetna has responded to surgeon and patientrequests, as well as our own appeal submission, to review and update theircoverage policy for these patients that have been facing difficult treatmentdecisions. We will continue to review coverage policy with several otherinsurance carriers that have referenced Aetna's previous position in their owncoverage policy statements," commented Steven Ek, COO.

Metatarsal head resurfacing with the HemiCAP(R) implant provides a moderntreatment approach for patients with Grade II and early Grade III MTP changes.This intermediate patient population can be served with a motion-preservingsurgical alternative for providing pain relief and functional improvement.

The metatarsal phalangeal joint or great toe is considered one of the mostcommon osteoarthritic joints and the often painful condition of hallux rigidusis reported to be present in females at a rate of 2:1 over males. Theunderlying disease process of hallux rigidus is not fully understood but it isbelieved to be associated with joint impingement diseases and previous traumassuch as sports or occupational injuries.

Arthrosurface is a medical device manufacturer specializing in thedevelopment of cartilage resurfacing systems targeted for the middle aged andactive patient. The company's systems are indicated and FDA cleared for usein the knee, shoulder, hip and toe.

SOURCE Arthrosurface, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
PharmMD Adds Belmont, Nukote and SVP Worldwide as ...
Statement by American Heart Association President ...